Research ArticleClinical Studies
Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC)
PATRIK PALACKA, JAN SLOPOVSKY, JANA OBERTOVA, MICHAL CHOVANEC, KATARINA REJLEKOVA, ZUZANA SYCOVA-MILA, BORIS KOLLARIK, JOZEF MARDIAK and MICHAL MEGO
Anticancer Research November 2021, 41 (11) 5749-5759; DOI: https://doi.org/10.21873/anticanres.15391
PATRIK PALACKA
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
JAN SLOPOVSKY
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
JANA OBERTOVA
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
MICHAL CHOVANEC
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
KATARINA REJLEKOVA
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
ZUZANA SYCOVA-MILA
2National Cancer Institute, Bratislava, Slovak Republic;
BORIS KOLLARIK
3Department of Urology, University Hospital in Bratislava, Bratislava, Slovak Republic
JOZEF MARDIAK
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;
MICHAL MEGO
12nd Department of Oncology, Comenius University, Faculty of Medicine in Bratislava, Bratislava, Slovak Republic;
2National Cancer Institute, Bratislava, Slovak Republic;

Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
patientACCESS
patientACCESS - Patients desiring access to articles
In this issue
Anticancer Research
Vol. 41, Issue 11
November 2021
Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC)
PATRIK PALACKA, JAN SLOPOVSKY, JANA OBERTOVA, MICHAL CHOVANEC, KATARINA REJLEKOVA, ZUZANA SYCOVA-MILA, BORIS KOLLARIK, JOZEF MARDIAK, MICHAL MEGO
Anticancer Research Nov 2021, 41 (11) 5749-5759; DOI: 10.21873/anticanres.15391
Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC)
PATRIK PALACKA, JAN SLOPOVSKY, JANA OBERTOVA, MICHAL CHOVANEC, KATARINA REJLEKOVA, ZUZANA SYCOVA-MILA, BORIS KOLLARIK, JOZEF MARDIAK, MICHAL MEGO
Anticancer Research Nov 2021, 41 (11) 5749-5759; DOI: 10.21873/anticanres.15391
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.